Diplomat Pharmacy, Inc. (NYSE:DPLO) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday. The brokerage currently has a $24.00 price target on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 13.69% from the company’s current price.
According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “
Other research analysts also recently issued research reports about the company. TheStreet raised Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research note on Thursday, August 10th. BidaskClub upgraded Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 5th. Needham & Company LLC initiated coverage on Diplomat Pharmacy in a report on Friday, July 21st. They issued a “buy” rating and a $19.75 target price on the stock. Finally, Robert W. Baird upgraded Diplomat Pharmacy to a “positive” rating and upped their target price for the company from $20.00 to $24.00 in a report on Monday, September 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $19.69.
Diplomat Pharmacy (NYSE DPLO) traded up 2.13% during trading on Tuesday, reaching $21.11. 552,697 shares of the company traded hands. Diplomat Pharmacy has a 12 month low of $12.25 and a 12 month high of $29.36. The company has a market cap of $1.44 billion, a PE ratio of 115.36 and a beta of 0.73. The company’s 50-day moving average is $19.01 and its 200 day moving average is $16.92.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, August 7th. The company reported $0.25 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.10. The business had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.14 billion. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. Diplomat Pharmacy’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.23 earnings per share. On average, analysts anticipate that Diplomat Pharmacy will post $0.75 earnings per share for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Frontier Capital Management Co. LLC grew its position in shares of Diplomat Pharmacy by 4.1% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 5,677,230 shares of the company’s stock worth $84,023,000 after buying an additional 221,769 shares during the last quarter. BlackRock Inc. boosted its position in shares of Diplomat Pharmacy by 158,977.3% during the first quarter. BlackRock Inc. now owns 5,548,617 shares of the company’s stock valued at $88,501,000 after purchasing an additional 5,545,129 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Diplomat Pharmacy during the second quarter valued at approximately $67,476,000. Vanguard Group Inc. boosted its position in shares of Diplomat Pharmacy by 5.4% during the second quarter. Vanguard Group Inc. now owns 4,077,145 shares of the company’s stock valued at $60,342,000 after purchasing an additional 210,334 shares in the last quarter. Finally, Davis Selected Advisers boosted its position in shares of Diplomat Pharmacy by 4.4% during the second quarter. Davis Selected Advisers now owns 1,703,992 shares of the company’s stock valued at $25,219,000 after purchasing an additional 71,846 shares in the last quarter. Institutional investors and hedge funds own 69.90% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.